- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03194152
Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population
Effects of Peanut Consumption on Cardiovascular Disease Risk Factors and Gut Microbiota Among Adults in China: A Randomized Controlled Trial
This is a 2 parallel-arm randomized controlled study with free-living subjects on self-selected diets. The objective of this study is to compare the effects of two servings of peanuts with an isocaloric matched refined carbohydrate snack food on glucose, lipids and lipoproteins and cardiovascular health risk factors, satiety and gut microbiota in 250 Chinese participants at risk for metabolic syndrome (overweight/obese, enlarged waist circumference, elevated LDL-cholesterol, prehypertension, and/or prediabetes).
The investigators hypothesize that the inclusion of 2 serving of peanuts in the diet will decrease blood glucose, LDL-cholesterol, and improve satiety sanctification between meals and gut microbiota compared to the control group and baseline.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Emerging evidence has shown that peanut consumption has beneficial effects in modifying lipid profiles, glucose, and other cardiometabolic risk factors. During the last two decades, China has experienced a dramatic increase in T2D prevalence largely due to rapid social and economic growth. Peanuts are commonly consumed as snacks in China. However, there is limited evidence on the specific health benefits of peanuts as part of the Chinese habitual diet.
Clinical Study Protocol
Study diet Subjects will consume their habitual diet with the test snacks provided as roasted peanuts and rice flour snack bars twice a day during a mid- morning snack and mid -afternoon snack. Subjects in the peanut group will consume two serving of peanuts and subjects in the control group will consume isocaloric rice bars on a daily basis under on site supervision. Subjects will be instructed to maintain their habitual diet and physical activity. During the study period, body weight will be monitored routinely to ensure that baseline weight does not fluctuate by more than 1kg. Prior to day 1, day 42 and day 84, a three-day diet record will be administered to subjects to calculate basal energy intake.
Study design The study is a randomized, controlled, parallel-arm trial precedes by a 1-week run-in period with control treatment to assess compliance, acceptability and to determine baseline values.After the run-in period, participants will be randomized to either the control group or treatment group for three months. Each treatment phase will be 3 months in duration. At baseline, day 42 and day 84, clinical assessment (body weight, waist/hip circumference, blood pressure, pulse) will be preformed and blood samples will be collected. Urinary will be collected on baseline, day 42 and day 84. Fecal samples will be collected on baseline and day 84. Three days dietary records and appetite sensation ratings will be collected three times during the study (baseline, day 42 and day 84).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200040
- Liang Sun
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 20-65
- Increased waist circumference : ≥ 90 cm for men and ≥ 80 cm for women
Plus 1 or more of the remaining criteria:
- Elevated TG level ≥ 1.7 mmo/L
- Reduced HDL-Cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women)
- Fasting glucose ≥ 5.6 mmol/L
- Systolic/diastolic blood pressure ≥ 130/85 mmHg.
Exclusion Criteria:
- Taking lipid lowering medications
- With known or unknown peanut allergy (or any peanut containing products)
- Thyroid disease
- Diabetes mellitus
- Kidney disease
- Liver disease
- Cardiovascular disease or cancer
- Pregnant or lactating women
- Heavy alcohol consumption (>14 drinks/week)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Peanut
Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
|
Dietary Supplement: Peanut
|
Experimental: Control
Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
|
Dietary Supplement: High carbohydrate snacks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose
Time Frame: Blood glucose will be measured at day 84.
|
glucose, insulin, HbA1c
|
Blood glucose will be measured at day 84.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood lipids level
Time Frame: Blood lipids level will be measured at day 84.
|
cholesterol and triglyceride levels
|
Blood lipids level will be measured at day 84.
|
Blood Inflammatory status
Time Frame: Inflammatory biomarkers will be measured at day 84.
|
Inflammatory biomarkers
|
Inflammatory biomarkers will be measured at day 84.
|
Assessment of appetite and other hunger sensations
Time Frame: Appetite and other hunger sensations will be measured at day 84.
|
Appetite and other hunger sensations will be assessed using visual analogue scales
|
Appetite and other hunger sensations will be measured at day 84.
|
Microbiome
Time Frame: Micriobiome will be measured at day 84.
|
fecal microbiome (subset) A subset of study subjects will be measured for fecal microbiome functionality.
|
Micriobiome will be measured at day 84.
|
Polyphenol metabolites
Time Frame: Polyphenol metabolites will be measured at day 84.
|
Urinary polyphenol metabolites (subset)
|
Polyphenol metabolites will be measured at day 84.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xiaoran Liu, PhD, Harvard School of Public Health (HSPH)
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB17-0703
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on T2D
-
Peking University Third HospitalNot yet recruiting
-
University of CopenhagenNovo Nordisk A/S; Steno Diabetes Center CopenhagenCompleted
-
Nantes University HospitalUniversity Hospital, AngersRecruiting
-
Virginia Commonwealth UniversityCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedT2D | IGT - Impaired Glucose ToleranceUnited States
-
NYU Langone HealthCompletedAtherosclerosis | Type 2 Diabetes (T2D)United States
-
Eli Lilly and CompanyActive, not recruitingType 2 Diabetes | T2DUnited States, Mexico, Argentina, Puerto Rico
-
Merck Sharp & Dohme LLCCompleted
-
University Hospital, MontpellierCompletedInsulin Resistance | Healthy Volunteers | Type 2 Diabetes (T2D)France
-
Indonesia UniversityDr Cipto Mangunkusumo General HospitalUnknown
Clinical Trials on Peanut
-
Johns Hopkins UniversityIcahn School of Medicine at Mount SinaiWithdrawnPeanut Allergy | Food Allergy
-
Johns Hopkins UniversityCompleted
-
University of North Carolina, Chapel HillTerminated
-
University of North Carolina, Chapel HillCompletedPeanut HypersensitivityUnited States
-
University of North Carolina, Chapel HillNational Center for Complementary and Integrative Health (NCCIH)CompletedFood Hypersensitivity | Peanut Hypersensitivity | Peanut Allergy | Food AllergyUnited States
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedFood HypersensitivityUnited States
-
University of North Carolina, Chapel HillCompleted
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut AllergyUnited States
-
Virginia Polytechnic Institute and State UniversityCompleted
-
North Carolina State UniversityTerminatedDiabetes Mellitus | Glycemic ControlUnited States